This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Integra LifeSciences Reports First Quarter 2013 Financial Results

Results In Line With Preliminary Announcement

Revises 2013 Guidance

PLAINSBORO, N.J., May 2, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the first quarter ending March 31, 2013. Total revenues for the first quarter were $196.7 million, reflecting an increase of $0.5 million over the first quarter of 2012. Currency exchange rates had a negligible effect on revenues.

The Company reduced its revenue in the quarter by $2.9 million because of product returned in the voluntary recall announced on April 10, 2013, and estimates that it was unable to satisfy customer demand for an additional $6 million to $7 million.

The Company reported GAAP net loss of $4.1 million, or $0.15 per diluted share, for the first quarter of 2013, compared to GAAP net income of $6.7 million, or $0.23 per diluted share, for the first quarter of 2012.

Adjusted net income for the first quarter of 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $10.9 million, or $0.39 per diluted share, compared to adjusted net income of $20.2 million, or $0.71 per diluted share, in the first quarter of 2012.

Integra generated $7.8 million in cash flows from operations and invested $10.9 million in capital expenditures during the quarter.

Adjusted EBITDA for the first quarter of 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $24.3 million, a decrease of 38% compared to $39.0 million achieved in the first quarter last year. Adjusted EBITDA excluding stock-based compensation for the first quarter of 2013, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $26.4 million, a decrease of 36% compared to $41.1 million achieved in the first quarter last year.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,076.57 -12.89 -0.62%
NASDAQ 4,911.3790 -27.9480 -0.57%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs